• As AI Reshapes Drug Discovery the Lab Remains the Bottleneck

    Bio-IT World | At a plenary session at the Bio-IT World Conference & Expo last month, Jeremy Jenkins, a computational drug discovery leader at Novartis, delivered a frank and wide-ranging assessment of where artificial intelligence is genuinely accelerating pharmaceutical R&D — and where it keeps running into the same old wall: biology.

    Jun 9, 2026
  • Federation Plus Fine Tuning: The Push for Federated Learning Models Continues

    Bio-IT World | Federated learning is changing the rules in drug discovery, argued a group of speakers at last month’s Bio-IT World Conference & Expo. The opportunities are robust, but success depends on establishing trust and fine-tuning models for individual applications.

    Jun 4, 2026
  • Trends from the Trenches: AI-Ready Life Sciences Data

    Bio-IT World | In the latest episode of Trends from the Trenches, Adam Marko, CTO of Life Science Field at Hammerspace, speaks with host Jessica StLouis about AI-ready data as a practical outcome. Researchers see one familiar file system, while the platform handles where data lives, how it moves, and who can access it. That shift reduces “data friction,” allowing scientists to spend less time hunting files and more time conducting research.

    Jun 3, 2026
  • A ‘Credit-Score-Like’ Risk Assessment System for Investigative Drugs

    Bio-IT World | VeriSIM Life is building the “full-stack predictive infrastructure” to help pharma companies foresee the challenges ahead in translating a molecule from laboratory discovery to a successful human therapy. The help comes in the form of a dynamic, “credit-score-like” assessment of the risk with inherent explainability and trust.

    Jun 2, 2026